Brevis

Brevis Bio is a biotechnology company specializing in ultra-high-throughput protein engineering and discovery. The company's proprietary platform combines microfluidics, DNA sequencing, and machine learning to screen millions of protein variants in parallel, drastically reducing the time required to identify therapeutic candidates. By focusing on the optimization of protein function, stability, and binding affinity, Brevis Bio aims to develop next-generation biologics for challenging targets in oncology and immunology. The company was founded by leading researchers from Stanford University and is backed by prominent venture capital firms including Andreessen Horowitz.